Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review

被引：17

作者：

Farhadfar, Nosha ^{[1
]}

Cerquozzi, Sonia ^{[1
]}

Patnaik, Mrinal ^{[1
]}

Tefferi, Ayalew ^{[1
]}

机构：

[1] Mayo Clin, Rochester, MN USA

来源：

JOURNAL OF ONCOLOGY PRACTICE | 2016年 / 12卷 / 07期

关键词：

INTERNATIONAL WORKING GROUP; PROGNOSTIC SCORING SYSTEM; SINGLE-INSTITUTION EXPERIENCE; DONOR-LYMPHOCYTE INFUSION; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASMS; IDIOPATHIC MYELOFIBROSIS; MARROW TRANSPLANTATION; PERIPHERAL-BLOOD; GRAFT FAILURE;

D O I：

10.1200/JOP.2016.013268

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Myelofibrosis is a myeloproliferative neoplasm with cardinal features of extramedullary hematopoiesis, hepatosplenomegaly, cytopenias, and constitutional symptoms that result in shortened survival and leukemic transformation. It is a disease predominantly of the elderly, and currently available therapies only offer symptom control without curative benefit or ability to alter disease progression. Allogeneic hematopoietic stem-cell transplant (HSCT) is the only potentially curative intervention; however, this is only feasible in younger and medically fit patients and selectively offered to those with high-risk disease. Despite ongoing advancements, HSCT is associated with substantial morbidity and mortality, and the determination of which patients with myelofibrosis are ideal candidates and the selection of the opportune moment to proceed with transplantation remains challenging. This review summarizes our current recommendations for the role of and indications for HSCT in myelofibrosis.

引用

页码：611 / +

页数：12

共 66 条

[1] The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries [J].

Abelsson, J. ;

Merup, M. ;

Birgegard, G. ;

WeisBjerrum, O. ;

Brinch, L. ;

Brune, M. ;

Johansson, P. ;

Kauppila, M. ;

Lenhoff, S. ;

Liljeholm, M. ;

Malm, C. ;

Remes, K. ;

Vindelov, L. ;

Andreasson, B. .

BONE MARROW TRANSPLANTATION, 2012, 47 (03) :380-386

[2] Effects of spleen status on early outcomes after hematopoietic cell transplantation [J].

Akpek, G. ;

Pasquini, M. C. ;

Logan, B. ;

Agovi, M-A ;

Lazarus, H. M. ;

Marks, D. I. ;

Bornhaeueser, M. ;

Ringden, O. ;

Maziarz, R. T. ;

Gupta, V. ;

Popat, U. ;

Maharaj, D. ;

Bolwell, B. J. ;

Rizzo, J. D. ;

Ballen, K. K. ;

Cooke, K. R. ;

McCarthy, P. L. ;

Ho, V. T. .

BONE MARROW TRANSPLANTATION, 2013, 48 (06) :825-831

[3] Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis [J].

Alchalby, Haefaa ;

Badbaran, Anita ;

Zabelina, Tatjana ;

Kobbe, Guido ;

Hahn, Joachim ;

Wolff, Daniel ;

Bornhaeuser, Martin ;

Thiede, Christian ;

Baurmann, Herrad ;

Bethge, Wolfgang ;

Hildebrandt, York ;

Bacher, Ulrike ;

Fehse, Boris ;

Zander, Axel R. ;

Kroeger, Nicolaus .

BLOOD, 2010, 116 (18) :3572-3581

[4] Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors [J].

Anasetti, Claudio ;

Logan, Brent R. ;

Lee, Stephanie J. ;

Waller, Edmund K. ;

Weisdorf, Daniel J. ;

Wingard, John R. ;

Cutler, Corey S. ;

Westervelt, Peter ;

Woolfrey, Ann ;

Couban, Stephen ;

Ehninger, Gerhard ;

Johnston, Laura ;

Maziarz, Richard T. ;

Pulsipher, Michael A. ;

Porter, David L. ;

Mineishi, Shin ;

McCarty, John M. ;

Khan, Shakila P. ;

Anderlini, Paolo ;

Bensinger, William I. ;

Leitman, Susan F. ;

Rowley, Scott D. ;

Bredeson, Christopher ;

Carter, Shelly L. ;

Horowitz, Mary M. ;

Confer, Dennis L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (16) :1487-1496

[5] Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type [J].

Bacigalupo, A. ;

Soraru, M. ;

Dominietto, A. ;

Pozzi, S. ;

Geroldi, S. ;

Van Lint, M. T. ;

Ibatici, A. ;

Raiola, A. M. ;

Frassoni, F. ;

De Stefano, F. ;

Verdiani, S. ;

Casarino, L. ;

Barosi, G. .

BONE MARROW TRANSPLANTATION, 2010, 45 (03) :458-463

[6] Outcome of Transplantation for Myelofibrosis [J].

Ballen, Karen K. ;

Shrestha, Smriti ;

Sobocinski, Kathleen A. ;

Zhang, Mei-Jie ;

Bashey, Asad ;

Bolwell, Brian J. ;

Cervantes, Francisco ;

Devine, Steven M. ;

Gale, Robert Peter ;

Gupta, Vikas ;

Hahn, Theresa E. ;

Hogan, William J. ;

Kroeger, Nicolaus ;

Litzow, Mark R. ;

Marks, David I. ;

Maziarz, Richard T. ;

McCarthy, Philip L. ;

Schiller, Gary ;

Schouten, Harry C. ;

Roy, Vivek ;

Wiernik, Peter H. ;

Horowitz, Mary M. ;

Giralt, Sergio A. ;

Arora, Mukta .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (03) :358-367

[7] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[8]

Byrne JL, 2000, BRIT J HAEMATOL, V108, P430

[9] Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect [J].

Cervantes, F ;

Rovira, M ;

Urbano-Ispizua, A ;

Rozman, M ;

Carreras, E ;

Montserrat, E .

BONE MARROW TRANSPLANTATION, 2000, 26 (06) :697-699

[10] New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment [J].

Cervantes, Francisco ;

Dupriez, Brigitte ;

Pereira, Arturo ;

Passamonti, Francesco ;

Reilly, John T. ;

Morra, Enrica ;

Vannucchi, Alessandro M. ;

Mesa, Ruben A. ;

Demory, Jean-Loup ;

Barosi, Giovanni ;

Rumi, Elisa ;

Tefferi, Ayalew .

BLOOD, 2009, 113 (13) :2895-2901

← 1 2 3 4 5 6 7 →